Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's ...

Quest Diagnostics will offer Roche’s FDA-cleared Elecsys pTau217 blood test, the first single-biomarker test able to both confirm and rule out amyloid pathology for Alzheimer's disease, integrating it with its own multi-biomarker panel for broader diagnostic use starting late 2026. This blood-based testing offers a less invasive, more accessible and cost-effective alternative to traditional PET scans or spinal tap diagnostics.

This Wire brief sits within Fusion42's coverage of Health, and 6 sources have reported it between 24 Aug 2026 and 26 Aug 2026.